Advancing non-hormonal therapies in women's health
Advancing non-hormonal therapies in women's health
Advancing non-hormonal therapies in women's health
Advancing non-hormonal therapies in women's health
Tioga is a privately held, clinical-stage pharmaceutical company dedicated to developing non-hormonal therapies in women's health. We operate with a lean, experienced team and work closely with academic investigators and clinical partners. Our goal is to advance scientifically grounded, well-characterized women's health therapies in areas of unmet medical need, particularly for women who may not be candidates for hormone therapy during menopause. Tioga is preparing for upcoming clinical milestones in 2026.
Standish Fleming, MBA – Chief Executive Officer.
Mr. Fleming brings extensive experience in company formation, financing, and governance in the life sciences sector, particularly in the clinical-stage pharmaceutical industry.
Helen Rosenberg – Vice President of Accounting and Finance. Mrs. Rosenberg has extensive experience as a senior finance and fundraising executive in entrepreneurial companies, including biotechnology start-ups.
Sergey Sikora, PhD – Clinical Development Lead.
Dr. Sikora has led multiple clinical programs in women’s health and cardiovascular indications, with a focus on Phase II and Phase III trial design and execution.
Tioga is developing a clinical-stage pharmaceutical lead program that offers an investigational, non-hormonal therapy aimed at managing vasomotor symptoms (VMS) associated with menopause.
More information is available on the ongoing Clinical Proof of Concept study (NCT# 07042516).
This therapy is still in the investigational phase and has not yet received approval from the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No claims regarding safety or efficacy are made.

Asimadoline is a clinical-stage molecule that acts as a Peripherally Restricted Kappa Opioid Receptor (KOR) Agonist.

Asimadoline is a selective, peripherally acting kappa-opioid receptor agonist, which modulates peripheral sensory and autonomic pathways involved in thermoregulation. Its action is asserted through suppression of the KNDy neuron signaling.
Mon | 09:00 am – 05:00 pm | |
Tue | 09:00 am – 05:00 pm | |
Wed | 09:00 am – 05:00 pm | |
Thu | 09:00 am – 05:00 pm | |
Fri | 09:00 am – 05:00 pm | |
Sat | Closed | |
Sun | Closed |
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.